BIOMEDICAL RESEARCH AND THERAPY

Indexed and abstracted by Web of Science, Scopus, Embase, Index Copernicus, Ebsco, Google Scholar

Skip to main content Skip to main navigation menu Skip to site footer

 Case report

HTML

242

Total

63

Share

Complete response of Palbociclib in metastatic breast cancer patient: A case report





Downloads

Download data is not yet available.

Abstract

Palbociclib, an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6), has been approved for metastatic breast cancer (mBC) treatment of hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative. The study reported the efficacy of Palbociclib as a new oral drug in a patient with mBC. A 40-year-old female with stage 2 right BC change to stage 4 after about two years later referred to oncology clinic. Due to HR-positivity/HER2-negative, she has treated with Palbociclib 125 mg (per one day for twoweek and one-week intervals) with Letrozole. In new assessment and after 8 months of this oral combination therapy, the chest x-ray of lung showed the complete response. Treatment with Palbociclib plus Letrozole had a complete response in the mBC patient after the common chemotherapies and hormone monotherapy.

Background

Breast cancer (BC) is the most frequent cancer among females that can be a leading problem of death through middle-aged females [1] . Palbociclib as an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) present a critical function in cell cycle regulation [2] . Nowadays, this drug has been approved for the treatment of mBC of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative [3] . Data show that Palbociclib is increased the response rate and duration in postmenopausal females with locally advanced or metastatic estrogen receptor (ER)-positive/HER2-negative BC [4] . This case showed the efficacy of Palbociclib as a new oral drug in mBC.

Case History

A 40-year-old female with stage 2 right BC referred to oncology clinic after modified radical mastectomy and axillary lymphadenectomy on March 16, 2014. In the history of the patient, hyperlipidemia, urinary tract infection, fatty liver grade 2 and ovarian cyst reported. She was treated with Epirubicin plus Paclitaxel for six cycles. After this treatment, the patient had the complaint of pain foot. Whole body scan showed bone metastases and the new pathology report was compatible with invasive and in situ (40%) or mixed mucinous ductal carcinoma of mBC. In immunohistochemistry staining for the tumor showed ER (Positive 1+), progesterone receptor (Positive 2+), Her2 (negative), Ki-67 (40% positive in tumoral cells), and P53 (Positive). She got 25 sessions of radiotherapy during 8 months and then was treated with Tamoxifen. Unfortunately, she went to worse condition with complaints of dyspnea. Chest computed tomography scan showed left lung metastasis in May 14, 2016 ( Figure 1 ).

Figure 1. Chest x-ray of left lung before treatment

She was treated with Paclitaxel plus Carboplatin for eight courses. On November 15, 2016, due to hormone receptor-positivity/Her2-negative, she was treated with Palbociclib 125 mg (per one day for two-week and one-week intervals) with Letrozole. Before treatment of Palbociclib, Platelet, WBC, and hemoglobin (Hb) were the normal that after one course of this new treatment, WBC, Hb, and platelet became 3300, 11.5, and 57000, respectively, but they returned to normal range again in other courses. In the new assessment and after 8 months of this oral combination therapy, the chest x-ray of lung showed the complete response (clearing metastasis) ( Figure 2 ). She is alive On March 1, 2018.

Figure 2. Chest x-ray of left lung after treatment

List of abbreviations

CDK: cyclin-dependent kinases; ER: estrogen receptor; Hb: hemoglobin; HER2: human epidermal growth factor receptor 2; HR: hormone receptor; mBC: metastatic breast cancer; Rb: retinoblastoma protein

Ethics approval and consent to participate

Not to be applied.

Competing interests

The authors declare that they have no conflicts of interest.

Funding

None.

Authors’ contributions

Mehrdad Payandeh & Edris Sadeghi: Literature search, Clinical studies, Data acquisition, Data analysis; Edris Sadeghi: Manuscript preparation, Manuscript review, Guarantor; Masoud Sadeghi: Concepts, Design, Definition of intellectual content, Literature search, Manuscript editing. Mehrnoush Aeinfar & Saba Yari: Manuscript editing.

References

  1. SH Madani, M Payandeh, M Sadeghi, H Motamed, E Sadeghi. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology. 2016;37:95. View Article PubMed Google Scholar
  2. AJ Walker, S Wedam, L Amiri-Kordestani, E Bloomquist, S Tang, R Sridhara, W Chen, TR Palmby, JF Zirkelbach, al Fu W et. FDA approval of Palbociclib in combination with Fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clinical Cancer Research. 2016;22:4968-4972. View Article PubMed Google Scholar
  3. Administration D. Food US. Palbociclib. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm. . March 31, 2017;:. Google Scholar
  4. RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, R Patel, T Pinter, M Schmidt. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2- negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The lancet oncology. 2015;16:25-35. View Article Google Scholar
  5. HJ Bowles, KL Clarke. Palbociclib: a new option for front-line treatment of metastatic, hormone receptor-positive, HER2-negative breast cancer. Journal of the advanced practitioner in oncology. 2015;6:577. PubMed Google Scholar
  6. RS Finn, M Martin, HS Rugo, S Jones, SA Im, K Gelmon, N Harbeck, ON Lipatov, JM Walshe, S Moulder. Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine. 2016;375:1925-1936. View Article PubMed Google Scholar
  7. K Orbaugh, JC Ryan, L Pfeuffer. Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario. Journal of the advanced practitioner in oncology. 2016;7:550. PubMed Google Scholar
  8. NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, CH Bartlett, K Zhang. Palbociclib in hormone-receptor-positive advanced breast cancer. New England Journal of Medicine. 2015;373:209-219. View Article PubMed Google Scholar


Author's Affiliation
Article Details

Issue: Vol 5 No 6 (2018)
Page No.: 2365-2369
Published: Jun 23, 2018
Section: Case report
DOI: https://doi.org/10.15419/bmrat.v5i6.448

 Copyright Info

Creative Commons License

Copyright: The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 How to Cite
Payandeh, M., Sadeghi, E., Sadeghi, M., Aeinfar, M., & Yari, S. (2018). Complete response of Palbociclib in metastatic breast cancer patient: A case report. Biomedical Research and Therapy, 5(6), 2365-2369. https://doi.org/https://doi.org/10.15419/bmrat.v5i6.448

 Cited by

Article level Metrics by Paperbuzz/Impactstory
Article level Metrics by Altmetrics

 Article Statistics
HTML = 242 times
Download PDF   = 63 times
View Article   = 0 times
Total   = 63 times